Clinical trial NCT01898273: Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
Official title: Phase 2, Open-Label, Imaging Trial of I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Glioblastoma
Keywords: Glioma
Glioblastoma Multiforme
PET
Imaging
Radiopharmaceutical
Diagnostic
Lead sponsor: Cellectar Biosciences, Inc.
Sponsor class: INDUSTRY
First posted: 2013-07-12
Enrollment: 7
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The primary objective of this trial is to determine the optimal dose and imaging time point(s) of I-124-CLR1404 in subjects with newly diagnosed and recurrent glioma to be used in future trials.


Eligibility criteria: Inclusion Criteria:

* newly diagnosed glioblastoma or recurrent/suspected recurrent glioblastoma
* scheduled to undergo a clinically-indicated surgery or biopsy (specific cohorts)
* ECOG performance status of 0 to 2 (Appendix C)
* 18 years of age or older
* has the initiative and means to be compliant with the protocol and be within geographical proximity to make the required study visits
* has the ability to read, understand and provide written informed consent for the initiation of any study related procedures (or legal representative)
* if female of childbearing potential must have a negative pregnancy test within 24 hours of enrollment
* Women of childbearing potential and men who are able to father a child, must agree to use an effective method of contraception (e.g., oral contraceptives, double-barrier methods such as a condom and a diaphragm, intrauterine device, Norplant, Depo-Provera) during the study and for 45 days following the last dose of the study drug.

Exclusion Criteria:

* ongoing grade 2 or greater toxicities due to previous therapies. However, tolerable grade 2 adverse (e.g. neuropathy) events may be allowed at the discretion of the investigator.
* has following laboratory abnormalities

  * Platelets \< 100,000/μL
  * WBC \< 3000/μL
  * Hematocrit \< 22%
  * Serum creatinine \> 2.5 mg/dL
  * ALT \> 1.5 x ULN
  * Bilirubin \> 1.5 x ULN
* ongoing chronic immunosuppressive therapy
* history of hypersensitivity to iodine
* any other concomitant serious illness or organ system dysfunction which in the opinion of the investigator would either compromise subject safety or interfere with the evaluation of the safety of the test drug
* women of childbearing potential, or men who are able to father a child, unwilling to use a medically acceptable method of contraception during the trial
* pregnancy or breast-feeding
* inability to comply with the protocol
* use of any investigational drug within 4 weeks of dosing (unless a longer time period is required by local regulations or the investigational agent)

Primary outcomes:
measure: Optimal Imaging Parameters - Dose
timeFrame: 8 days
Secondary outcomes:
measure: Optimal Imaging Parameters - Imaging Time Point
timeFrame: 8 days
Other outcomes:
Locations:
city: Duarte
country: United States
facility: City of Hope
state: California
city: Tampa
country: United States
facility: Moffitt Cancer Center and Research Institute
state: Florida
city: Baltimore
country: United States
facility: University of Maryland School of Medicine
state: Maryland
city: Cleveland
country: United States
facility: Cleveland Clinic
state: Ohio
city: Columbus
country: United States
facility: Ohio State University Medical Center
state: Ohio
city: Kettering
country: United States
facility: Kettering Medical Center
state: Ohio
city: Philadelphia
country: United States
facility: Hospital of University of Pennsylvania
state: Pennsylvania
city: Madison
country: United States
facility: University of Wisconsin
state: Wisconsin
city: Milwaukee
country: United States
facility: Medical College of Wisconsin
state: Wisconsin
Study officials:
affiliation: University of Wisconsin, Madison
name: John Kuo, MD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: City of Hope Medical Center
name: Jana Portnow, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Pennsylvania
name: Abass Alavi, MD
role: PRINCIPAL_INVESTIGATOR
References: